Program
A randomised placebo controlled trial to evaluate the effect of the bisphosphonate, clodronate, on the incidence of metastases and mortality in patients with primary operable breast cancer.
Acute myeloid leukemia and myelodysplastic syndrome following doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the NSABP experience.
Delivering full planned dose on time (PDOT) chemotherapy (CT) while lowering the incidence of febrile neutropenia (FN) hospitalizations: Initial results from a prospective study providing Filgrastim support to high risk breast cancer patients (BCP).
Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198).
The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27.
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
The effect of tamoxifen on benign breast disease. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT).
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women.
Final survival analysis of the double-blind, randomized, multinational phase III trial of letrozole (Femara®) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer.
Letrozole (Femara®) is a more effective anti-proliferative agent than tamoxifen irrespective of ErbB1 and/or ErbB2 positive status: evidence from a phase III randomized trial of neoadjuvant endocrine therapy for postmenopausal women with estrogen receptor positive primary breast cancer.
A common progenitor (adult stem) cell gives rise to both the glandular and myoepithelial cell lineages. A new cell biological concept as the basis of breast pathology.
Risk of invasive local recurrence following therapy for ductal carcinoma in situ is a function primarily of time.
Endothelin-1 (ET-1) mediates pathological but not normal bone remodeling.
Prognosis following local recurrence after conservative surgery and radiation therapy for early-stage breast cancer.
The learning curve in sentinel node biopsy(SNB) in breast cancer: results from the ALMANAC trial.
A randomized trial comparing axillary dissection and axillary radiotherapy for early breast cancer: 15 year results.
Utilization of gene expression profiling to identify markers of disease recurrence in node-negative breast cancer.
Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization.
Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial.
Telomerase is a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR expression.
Persistence of occult metastatic cells in bone marrow of breast cancer patients despite systemic adjuvant treatment.
Persistence of solitary breast cancer cells in the secondary site: a possible source of tumor dormancy.
Genetic alterations in the progression of non-invasive to invasive breast cancer.
Primary bilateral breast cancers display different LOH and CGH profiles in both epithelial and stromal components.
A hypersensitive estrogen receptor α is common in invasive breast cancer.
Epirubicin/Docetaxel (ET) versus 5FU/Epirubicin/Cyclophosphamide (FEC) combinations as first line chemotherapy in patients with metastatic breast cancer [MBC].
Circulating extracellular domain of HER2 can be correlated with clinical response to chemotherapy in locally advanced breast cancer.
Inhibition of VEGF/KDR signaling by TSU-68 (SU6668), an oral anti-angiogenic agent, can synergistically enhance the anti-tumor activity of taxol; a new paradigm for breast cancer chemotherapy.
Therapeutic and chemopreventive effects of R115777, a farnesyl transferase inhibitor (FTI), on methylnitrosourea (MNU)-induced rat mammary cancer.
Dissection of cooperating genetic pathways involved in aggressive early onset breast cancer reveals mutually distinct roles for BRCA1 and HER2/neu genes.
Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma.
Intraoperative axillary sentinel lymph node touch imprints lack sensitivity in detecting metastatic breast carcinoma.
Intra-operative frozen section reliably predicts sentinel node status in patients with breast cancer.
Analysis of potential risk factors for failed localisation of axillary sentinel nodes in breast cancer.
Tumor burden in sentinel lymph node correlates with the size of the primary breast carcinoma.
Is management of the positive sentinel node different in elderly patients with breast cancer?
The significance of cytokeratin positive single cells in axillary sentinel nodes.
2-(fluorine-18)-fluoro-2-deoxy-D-glucose-positron emission tomography and sentinel lymph nodes in breast cancer.
Pulse oximeter changes with sentinel node biopsy in breast cancer.
Comparison of subareolar subcutaneous injection of blue dye versus peritumoral injection of technetium-labelled human albumin for identification of sentinel lymph nodes in breast cancer patients.
Incidence of lymph node metastases in infiltrating breast cancers of less than 10 mm.
The use of Doppler ultrasound to detect axillary metastasis in breast cancer.
The clinical significance of micrometastatic breast cancer in sentinel lymph node biopsies.
Prognostic factors associated with axillary lymph node metastases for invasive breast carcinoma in patients age 70 and older.
Predicting sentinel node involvement: Manchester experience.
Quality of life and arm mobility after axillary lymph node dissection versus sentinel lymph node biopsy.
The micro-metastasis on the axillary lymph node can be diagnosed by sentinel lymph node biopsy with intra-operative multi-section frozen pathology.
Sentinel lymph node micrometastases in small carcinoma: no need for axillary dissection?
Sentinel nodes sampling by endoscopy (a new technique about 45 cases).
The Nottingham prospective randomised trial comparing radio-guided surgery (ROLL) to wire-guidance for occult breast lesion localisation.
Freehand core biopsy of palpable breast lesions: an accurate predictor of tumour grade?
Stereotactic directional vacuum-assisted breast biopsy in 220 patients with microcalcifications: radiological and pathological correlation.
How good is needle biopsy for microcalcification in an unselected clinic population ('the real world')?
Utility of a localization device to improve excision of non-palpable breast lesions.
Pilot study of a novel 10-gauge cryo-based rotational core biopsy system.
The effects of dietary flaxseed on mammographic density.
Predicted probability of breast cancer susceptibility gene mutations.
Familial invasive breast cancer: clinical response to induction chemotherapy and/or radiotherapy in relation to BRCA1 mutation status.
Loss of androgen receptor expression in BRCA1 mutated tumors.
Impact of genetic risk assessment in newly-diagnosed breast cancer management.
A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue.
The effects of exemestane on bone and lipids in the ovariectomized rat.
Tamoxifen modifies mammographic density, a noninvasive marker of breast cancer risk.
Change in serum dehydroepiandrosterone, testosterone, insulin-like growth factor-1, and osteocalcin levels with the third generation selective estrogen receptor modulator arzoxifene (LY353381·HCI).
The study of Tamoxifen and Raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
A pilot prevention study of the aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women.
9-cis-retinoic acid suppresses mammary tumorigenesis in MMTV-ErbB2/Neu-transgenic mice.
Combined estrogen blockade of the breast with raloxifene and exemestane in postmenopausal women for breast cancer prevention.
Exemestane for the prevention of breast cancer in postmenopausal unaffected carriers of BRACA1/2 mutations - aromasin prevention study (ApreS).
Relevance of local relapse: long term follow up after breast conserving surgery in 2537 patients.
Predictors of systemic recurrence and impact of local failure among early stage breast cancer patients treated with breast conserving therapy.
The BASO II trial of adjuvant radiotherapy vs. none and tamoxifen .V. none in small, node negative, grade I tumours.
Low rate of ipsilateral breast tumor recurrence for patients with T3/T4 tumors treated with neoadjuvant chemotherapy followed by breast conserving therapy.
Neoadjuvant radiation therapy for breast cancer: a twenty-year experience.
Targeted intraoperative radiotherapy for breast cancer-a randomised trial.
Ultrasound-guided cryoablation of breast fibroadenomas at four institutions using a 2.4-mm probe: 6-12 month follow up.
MRI breast scans aid selection of breast conserving surgery following neoadjuvant chemotherapy.
Metaplastic carcinoma of the breast: surgical evaluation and treatment.
Is radiotherapy needed after breast conservation for small invasive breast cancers?
Breast size and the risk of local and distant recurrence in breast conserved and irradiated patients with early stage breast cancer: a retrospective review of 78 cases.
Breast conserving surgery without radiotherapy.
Reduction of dose to the coronary arteries using IMRT for locoregional post-mastectomy irradiation.
The value of three-dimensional radiation treatment planning in breast conservation.
Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial.
A practical IMRT method for the adjuvant treatment of breast cancer.
Double blind dose ranging study of strontium-89 chloride in bone metastases associated with breast cancer.
Effect of timing of breast radiation therapy (RT) on local control in women with breast conserving surgery (BCS) and adjuvant chemotherapy.
Doxorubicin-based chemotherapy and radiation increase cardiac perfusion changes in patients treated for left-sided breast cancer.
Intraoperative radiotherapy after breast conserving surgery in breast cancer patients.
Skin-sparing mastectomy with immediate breast reconstruction in women with early operable breast cancer.
Volume changes after Latissimus dorsi "miniflap" breast reconstruction.
Short term morbidity from axillary surgery in breast cancer.
The skin and nipple-areolar sparing subcutaneous mastectomy with immediate reconstruction as treatment for early breast carcinomas.
Whole genome LOH analysis of lobular and ductal breast cancers by Hu-SNP array.
Progestins induce insulin receptor substrate-1 and -2 expression in breast cancer cells.
Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cells.
Telomerase activity and deltion mutation of P16 gene in human breast cancer.
Suppression of in vitro invasion and in vivo growth of breast cancer induced by hepatocyte growth factor/scatter factor (HGF/SF) and HGF/SF producing fibroblasts, by viral hammerhead ribozymes targeting HGF/SF and its receptor cMET.
Identification of proteins associated with the AP-1 transcription factor that are critical for breast cancer growth.
The oral selective EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) potentiates taxane activity in multidrug-resistant MCF-7 ADR human breast cancer cells that overexpress the bcl-2 gene.
Growth inhibition of breast cancer cells by celecoxib.
Growth suppresion of breast cancer by uncoupling G-protein signaling cascades: a proposed mechanism of receptor blockade.
En face formalin treatment of paraffin sections leads to improved detection of EGFr by immunohistochemistry.
PDGF decreases insulin receptor substrate levels via PI3K-mediated proteasomal degradation.
Histone deacetylase inhibition increases expression and acetylation of ESX but paradoxically reduces ERBB2 transcript and protein levels.
The relationship between ARF, p53 and Mdm2 subcellular localisation in pre-invasive and invasive breast cancer.
Breast pathology in women with personal and family history of breast cancer, including BRCA1/2 mutation carriers: a model for cancer progression.
Upregulation of Her-2/neu under chemical castration: serum results of a randomized trial comparing leuprorelin acetate to CMF for adjuvant therapy of nodal-positive breast cancer.
The FKHR family - estrogen receptor co-repressors and potential tumor suppressors.
Single nucleotide polymorphisms (SNPs) within the ERBB2 genome.
Office ultrasound by breast surgeons: a rapid, accurate adjunct to clinical diagnosis.
Consequences of estrogen replacement therapy (ERT) on breast density in breast cancer survivors treated with ERT and breast conservation.
Detection of suspected metastatic breast carcinoma using image fusion of x-ray and nuclear medicine computed tomography with CEA-scan® (arcitumomab) - a murine fab′ monoclonal antibody.
Superior diagnostic accuracy of combined anatomical and functional imaging in diagnosis of breast cancer.
Laser doppler imaging in the detection of skin involvement in breast cancer.
Breast magnetic resonance imaging (MRI): a useful tool for therapeutic decision in patients treated for locally advanced breast cancer (LABC) by neoadjuvant chemotherapy (NCT).
Wolfe mammographic patterns as predictors of breast cancer risk.
The effects of environment on patient anxiety in the mammography waiting room.
Galactography verses ductal lavage.
Comparison of standard triple assessment and scintimammography in detecting primary breast cancer.
Initial evaluation of a novel dose-efficient system for full-field digital mammography.
A new measure of response to therapy in bone-dominant breast cancer: a pilot study of serial quantitative F-(18)-Fluorodeoxyglucose Positron Emission Tomography.
A comparative study on results of examining 80 cases with breast lumps by means of both molybdenum palladium roentgenography and ultrasonography.
Occult central nervous system (CNS) involvement in patients (pts.) with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.
The changing clinical presentation of contralateral breast cancer: trends for bilateral tumors since 1980, comparison with unilateral tumor stage, and the role of screening mammography.
Tumor markers and patient factors associated with the detection of breast cancer by screening mammography in New Mexico women.
British women's views on the introduction of annual screening mammography to those aged 40-49 years.
Do breast implants impact on the breast screening programme?
Can improved recording of clinical breast examination alert clinicians to increased risk of delayed diagnosis of breast cancer?
Overexpression of Her-2 neu as a prognostic factor and as a predictive factor for response to adjuvant combined endocrine therapy in premenopausal Vietnamese women with operable breast cancer.
Sensitization of breast cancer patients to vinorelbine following p53 induction and microtubule associated protein-4 repression by doxorubicin.
Is initial screening by fluorescence in situ hybridization necessary for accurate determination of HER-2/neu status in breast cancer?
Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study.
Serum and tissue c-erbB-2 antigen levels predicts outcome and response to hormonal therapy of bone metastatic breast cancer.
HER2: a predictive factor for response to induction anthracycline-based chemotherapy in primary operable breast cancers.
Decrease of serum hemoglobin during dose-intensified preoperative chemotherapy has no influence on tumor response: results from the German preoperative adriamycin/docetaxel (GEPARDO) trial.
Prognostic indicators of relapse-free and overall survival in patients with high-risk primary breast cancer following high-dose chemotherapy.
Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer.
Cyclin A is a novel modulator of tamoxifen treatment in early stage breast cancer.
Circulating angiogenic growth factors as predictive factors in metastatic breast cancer treated with letrozole.
Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment.
Significant association between in vitro extreme drug resistance assay results and breast cancer patient survival.
Do biological markers expressed by invasive lobular carcinomas account for low response to neoadjuvant chemotherapy?
Ki67/apoptotic index, a growth index for prediction of response to neo-adjuvant chemotherapy.
Response to neoadjuvant therapy for breast cancer by magnetic resonance imaging type, estrogen receptor status, grade, and comparative genomic hybridization.
Genetic markers of response to neoadjuvent therapy: array-based gene expression profiling from serial core biopsies.
Cyclin D1 predicts tamoxifen benefit in women with early stage ER+ breast cancer.
Predictive value of HER-2, p53, bcl-2, bax, MIB-1 and hormonal receptors status in adjuvant treatment breast cancer patients.
Development of a Cox proportional hazards (Cox-PH) model of time to first dose reduction in women undergoing breast cancer chemotherapy.
HER2-status as a predictive factor for pathological complete response in primary breast cancer patients treated with gemcitabine-adriamycin-taxol as neoadjuvant treatment.
A case-control comparison of risk factors in African-American and Caucasian women presenting with newly diagnosed breast cancer.
Risk factors for breast cancer aggressiveness.
Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer.
Reversibility of bone mineral density loss in pre-/perimenopausal patients with node-positive early breast cancer after treatment with Zoladex™: results from the ZEBRA study.
Tables of anticipated benefit from adjuvant therapy for the individual.
Dose-intense, dose-dense (F)AC+G adjuvant chemotherapy has excellent event-free survival in high-risk patients with 4-9 involved axillary nodes.
Immediate breast reconstruction is not associated with a delay in the delivery of adjuvant chemotherapy.
Randomized trial of equitoxic regimens of Cyclophosphamide, Methotexate, 5-FU (CMF) versus Adriamycin plus Cyclophosphamid (AC): can dose escalation of the CMF regimen compensate for the absence of anthracyclines (Anths)?
Sequential dose-dense epirubicin/paclitaxel followed by dose-dense CMF for resectable high-risk breast cancer patients - first toxicity evaluation of a randomized multicenter trial.
Do treatment recommendations from a multidisciplinary breast cancer conference differ from established practice guidelines?
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel (taxol®) and CMF (E-T-CMF) vs epirubicin and CMF (E-CMF) in high-risk patients with breast cancer (BC).
Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827.
Recurrence and outcome after treatment of ductal carcinoma in-situ of the breast.
An evaluation of micrometastasis in ductal carcinoma in situ (DCIS).
Mammographic density and breast cancer after ductal carcinoma in situ.
STK15/BTAK/aurora-A expression in ductal carcinoma in situ of the breast.
Oestrogen withdrawal reduces cell proliferation in oestrogen receptor (ER) positive ductal carcinoma in situ (DCIS).
Receptor expression in ductal carcinoma in situ (DCIS).
Ductal carcinoma in situ component confers an improved prognosis in early T1N1M0 breast cancer patients.
Are cell polarization and mitotic activity important prognostic factors for ipsilateral local recurrence in patients with DCIS operated with breast conserving surgery?
Economic evaluation of adjuvant therapy in node-positive breast cancer: a comparison between doxorubicin & cyclophosphamide plus paclitaxel (AC-T) and cyclophosphamide, epirubicin and 5-fluorouracil (CEF).
Cost utility analysis of first line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to tamoxifen.
A comparison of the direct healthcare costs following disease progression (DP) with anastrozole (AN) and tamoxifen (TAM) in the first-line treatment of postmenopausal (PM) patients (pts) with advanced breast cancer (ABC).
Pharmacoeconomic analysis of Xeloda (capecitabine) in combination with docetaxel for the treatment of advanced breast cancer pretreated with anthracyclines.
Adapting a population cost-effectiveness model for capecitabine-docetaxel combination therapy for metastatic breast cancer.
Identification of angiogenesis in primary breast carcinoma according to the image analysis.
Evaluation of intratumoral vessel maturation in a series of 17 breast carcinomas.
Preliminary clinical experience with angiogenesis-related tumor markers in breast cancer.
Low bcl-2 expression is correlated with accumulated p53 protein, low bFGF content and, poor prognosis in primary breast cancer.
Chemoprevention of mammary carcinoma by inhibition of angiogenesis.
Microvessel density is higher in invasive micropapillary carcinoma than in tubular carcinoma of the breast.
Onset of endocrine resistance in breast cancer is associated with increased active p38 MAPK.
Cross-resistance of tamoxifen and raloxifene on the growth of raloxifene-resistant breast cancer cells in vivo and in vitro.
Effects of ICI 182,780 on tamoxifen-stimulated breast and endometrial cancer.
Loss of BRCA2 increases in vivo somatic mutation induction by ionising radiation.
Mutation in BRCA2 reduces use of error-free DNA repair by sister chromatid recombination and stimulates error-prone DNA repair by homology directed single-strand annealing.
Differential binding of p21WAF1 by an altered form of proliferating cell nuclear antigen present in breast cancer cells.
Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors.
Keratin-18 transfected human breast cancer cells exert a "benign" influence on adjacent wild type cells - a bystander effect with encouraging implications for a successful gene therapy.
Adenoviral GM-CSF gene transduction into breast cancer cells induced long-lasting antitumor immunity in mice.
Relationship of serial plasma osteopontin (OPN) levels to survival in metastatic breast cancer: interim analysis.
Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts).
Elevation of the serum HER2/neu and EGFR levels is associated with short progression-free survival in metastatic breast cancer.
Altered glycosylation in the serum c-erb-B2 protein product in human breast cancer.
Quantitation of circulating tumor cells in peripheral blood of breast cancer patients: correlation with stage and progression.
Detection of micrometastatic clonogenic growth in bone marrow of early stage breast cancer patients presenting with or without lymph node involvement.
Low incidence and absence of prognosis value of cancer cells in aphereses obtained from patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
Aneuploidy of epithelial cells in blood of breast cancer patients.
Analysis of bone marrow micrometastasis in primary breast cancer: automated cellular imaging analysis in relation to quantitative RT-PCR and tumor clinicopathologic features.
Relationship of body mass index to outcomes after lymph node-negative, estrogen receptor positive breast cancer.
Serum IL-6 (sIL-6) predicts overall survival in patients with metastatic breast cancer (MBC).
Identification of axillary lymph node positive breast cancer patients using microarray expression analysis.
Multivariate analyses of flow cytometric S-phase and ploidy as node-negative breast cancer prognostic factors: an international and multi-center study.
Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer.
PTEN: a potential prognostic marker in hormonally treated breast cancer.
The effect of stereotactic needle biopsy on the size and staging of T1 breast cancer.
Outcome in locally advanced breast cancer can be predicted by baseline tumor markers and post-chemotherapy nodal status.
Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: results from a National Cancer Institute of Canada randomized controlled trial.
Tumor markers of prognosis in 934 young women with breast cancer.
Actor (VEGF) expression in node-positive breast cancer.
C-myc, not HER-2/neu, correlates with early recurrence of node-negative breast cancers.
Prognostic value of UPA, PAI-1, and PAI-2 mRNA expression in primary breast cancer.
The Cytokeratin-19 mRNA expression in blood as a new prognostic factor for primary breast cancer patients.
Age is not an independent prognostic factor.
The number of resected lymph nodes is a prognostic factor that varied over time in node-negative breast cancer patients. A 29-year single institution experience in 2128 patients.
Histological grade, its three components, and flow cytometric S-phase as prognostic markers in premenopausal women with node-negative breast cancer.
Nipple aspirate fluid (NAF) cytology and pathologic parameters predict residual breast cancer and nodal spread after excisional biopsy.
Factors underlying the improvement in mortality from breast cancer.
Is youth a poor prognostic indicator in breast cancer?
Prognostic and predictive factors in primary breast cancer and its local recurrence by immunohistochemical analysis.
HER-2 overexpression in node negative breast cancer: prognostic significance and comparison with the Nottingham Prognostic Index.
Induced abortion as a predictor for HER2 (erbB-2/neu) overexpression in malignant breast tumors.
Expression and quantitation of lymphatic endothelial marker, LYVE-1, mRNA in breast cancer.
HER2-receptor overexpression and gene amplification in invasive lobular breast cancer.
The prognostic value of the mitotic activity index in primary breast cancer.
Low p27 in T1N0M0 breast cancers - association with other unfavorable molecular markers of prognosis.
High level of STK-15 expression in primary breast tumors correlates with nuclear grade.
Prediction of outcome in early stage primary breast cancer by c-erbB-2 and p53 immunostaining.
Prognosis of T1bN0M0 breast cancer in patients receiving breast conservation therapy.
Activation of phosphatidylinositol 3-kinase (PI3K) as a predictor of clinical outcome in breast cancer patients.
Competing-risk neural networks in breast cancer: generalization performance.
Use of a log-normal survival model for distant disease-free survival of primary breast cancer patients.
Incidence of discordance in the results of prognostic factors analyzed in various breast cancer specimens.
Evaluation of the LightCycler-HER2/neu DNA quantification kit, a polymerase chain reaction assay for the determination of HER2 status, in women with breast cancer: comparison with immunohistochemistry and fluorescence in situ hybridisation.
Quality and accuracy of breast cancer information on the World Wide Web.
Studying the effectiveness of videos in conveying medical information regarding breast cancer risks and the Study of Tamoxifen and Raloxifene (STAR) trial.
Has health education had any impact on the size of tumour at presentation in the UK?
Community outreach grants awarded by the affiliate network of the Susan G. Komen Breast Cancer Foundation.
Advocate involvement in the clinical trials process.
National Breast Cancer Coalition Fund's (NBCCF) Quality Care Initiative and Guide to Quality Breast Cancer Care.
Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results.
Capecitabine in association with epirubicin and docetaxel as a first line treatment in advanced breast cancer. A multicenter phase II study.
Phase I trial of continuous Taxotere, Adriamycin, and cyclophosphamide with G-CSF (conTAC).
Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer.
Every-other-week combination of gemcitabine and docetaxel as first-line therapy in advanced breast cancer patients: preliminary results from a phase II trial.
Increased brain metastasis detected in metastatic breast cancer patients receiving herceptin.
Capecitabine plus paclitaxel as first- or second-line therapy: a multicenter phase II study in metastatic breast cancer.
High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC). An ONCOPAZ and associated hospitals study.
Phase III study of three schedules of weekly paclitaxel (P) induction therapy in metastatic breast cancer (MBC): preliminary results.
Dose optimization of antineoplastics by phenotypic assessment modeling: docetaxel and the erythromycin breath test.
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with anthracycline and taxane refractory metastatic breast cancer (MBC).
TEXAS (Taxotere experience with anthracyclines study): an evaluation of docetaxel combined with epirubicin or doxorubicin as first line chemotherapy for metastatic breast cancer.
A phase II trial of weekly taxol (T) as single agent, first line therapy for HER-2/neu negative metastatic breast cancer patients.
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.
Role of epoetin alpha in maintaining hemoglobin and quality of life in breast cancer patients receiving adjuvant chemotherapy or chemoradiation.
Interaction of estrogen receptor and receptor-tyrosine kinases in human breast cancer cell lines.
Overexpression of cJun in breast cancer cells inhibits growth and induces cell death.
Her-2/neu suppresses RAR transcriptional activities in breast cancer cells in an Akt dependent manner.
The in vitro antineoplastic effect of the Oligomodulators™ BT 99-08, BT 99-25, and BT 99-45 on human breast cancer cell lines.
RXR-selective retinoids function independently of RAR and PPARγ to inhibit breast cell growth.
hTERT expression in human breast cancer and adjacent non-cancerous breast tissue.
The association between cyclo-oxygenase-2 expression and cell proliferation and angiogenesis in human breast cancer.
Role of AKT in chemotherapy-mediated cytotoxicity in MCF-7 breast cancer cells.
Hsp27 sensitizes breast cancer cells to paclitaxel.
O6-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma.
Is over-expression of protein kinase C alpha required to induce a hormone-independent phenotype in T47D breast cancer cells?
Clinical experience of long-term administration of high doses of verapamil in addition to chemotherapy in patients with metastatic breast cancer.
An in vitro study using proteomics to identify proteins involved in the development of tamoxifen resistance.
Integrin β1, steroid hormone-independent growth and breast cancer.
Analysis of HER2 status in breast cancer: a multicentre comparison of automated image analysis systems versus manual assessment.
Pathologic review of atypical hyperplasia identified by image-guided needle core breast biopsy: correlation with excision specimen.
E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid intraepithelial neoplasias.
HER2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA-1 mutation status in the OFBCR.
A morphological classification of breast in menstrual cycle.
Myoepithelial tumors of the breast: a stem cell lesion with myoepithelial and glandular differentiation.
Her2/neu status in locally advanced breast cancer.
Evaluation of a high throughput approach to assess Her-2 status using tissue microarrays and automated image analysis (ACIS).
The variation in expression of cytokeratin phenotypes in primary breast cancer.
Instability of telomerase activity (TA) in breast cancer samples as a function of storage time.
Risk of a second primary breast cancer among women diagnosed with a first primary cancer: data from the Surveillance, Epidemiology, and End Results (SEER) program.
Breast cancer (BrCa) mortality reduction in British Columbia (B.C.) over the last 25 years: Impact of medical interventions (MedInter) including adjuvant chemoradiation (CT-RT), tamoxifen (T), and screening mamograms/education (Scr/E).
Testosterone, a potential hormonal marker associated with the presence of breast cancer in postmenopausal women.
The impact of estrogen receptor status in the Surveillance, Epidemiology, and End Results database.
Tissue case-controls: what is normal?
Functional mapping of metastases.
Clinical features and survival analysis of 848 Asian women with invasive breast cancer: results from a single institution in Singapore.
Lymphedema prevalence in a sample of breast cancer patients in Rio de Janeiro, Brazil.
Clinicopathologic and flow cytometry features in African American and Caucasian breast cancer patients.
Higher birth weights may be related to increased risk of aggressive breast cancer in young African-American women.
Retrospective analysis of breast cancer among young African American females.
Effect of filgrastim priming dose on peripheral blood progenitor cell yield, engraftment, and survival in women undergoing high dose chemotherapy for breast cancer.
Activity of docetaxel (DTX)+vinorelbine(VRB) in patients with metastatic breast cancer(MBC) progressing after high-dose chemotherapy with stem cell support(SCS).
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: comparison of survival for patients who underwent tandem vs. single transplants.
Tandem high-dose chemotherapy as adjuvant in stage IIIb inflammatory breast cancer.
Control of locally recurrent breast cancer with intratumoral cisplatin/epinephrine injectable gel.
Cardiac safety and efficacy of TLC D99 (D, Myocet™) and Herceptin® (H) in advanced breast cancer (ABC).
TSU-68 (SU6668), an anti-angiogenic agent, shows stronger anti-tumor effects against higher VEGF productive and more hypervascular tumors, which are poor prognostic factors in breast cancers.
Weekly herceptin with navelbine in chemonaïve patients with HER2 positive metastatic breast cancer: a phase II multicenter trial.
Usefulness of oral chemoendocrine therapy (doxifluridine + medroxyprogesterone acetate + cyclophosphamide) for advanced or metastatic breast cancer.
A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer.
Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer.
Early results of a phase I/II dose escalating trial of liposomal doxorubicin (TLC D-99, Myocet™) in combination with paclitaxel (Taxol®) for patients (pts) with metastatic breast cancer (MBC).
Phase II study of capecitabine (Xeloda®) in pts with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes.
Serum and tissue kinetics of liposomal encapsulated doxorubicin (Caelyx) in advanced breast cancer patient.
A phase I study of diethylnorspermine (DENSPM) in previously treated patients with metastatic breast cancer (MBC).
A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta®, multitargeted antifolate).
Cardiac safety of herceptin (H) in combination with epirubicin (E) plus cyclophosphamide (C): interim results of a phase II study in patients with metastatic breast cancer.
Phase II study of UFT plus leucovorin in women 65 years and older with advanced breast cancer.
Phase II study of pegylated liposomal doxorubicin (Caeylx)- monotherapy in previous treated metastatic breast cancer.
Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.
Characteristics of raloxifene-stimulated breast tumors in vivo.
The effect of alternating letrozole and tamoxifen in comparison to sequential treatment with each drug alone or in combination.
Effect of exemestane and celecoxib alone or in combination on DMBA-induced mammary carcinoma in rats.
Evidence of continued sensitivity to endocrine agents in postmenopausal women with advanced breast cancer progressing on fulvestrant ('Faslodex®') treatment.
Raloxifene stimulated endometrial cancer grown in athymic mice: cross resistance with ICI182,780 and antitumor action of estradiol.
A comparison of quality-adjusted time to disease progression (QATTP) of anastrozole (AN) vs tamoxifen (TAM) as the first-line treatment of postmenopausal (PM) patients (pts) with advanced breast cancer (ABC).
Use of letrozole as a chemopreventive agent in the aromatase overexpression transgenic mouse model.
Clinical and endocrine data for goserelin (Zoladex) plus anastrozole (Arimidex) as second line endocrine therapy in premenopausal women with advanced breast cancer.
Survival update from a phase II trial of fulvestrant ('Faslodex®') in tamoxifen-resistant breast cancer patients.
Fulvestrant ('Faslodex®') is effective in advanced breast cancer in postmenopausal patients with visceral metastases: comparison with anastrazole.
A multicenter study of pre-operative treatment with Femara® (Letrozole) for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer.
Distinct modulation of ER-α,β-mediated activity by TAS-108 (SR16234) may lead to unique intranuclear events in tumor, uterine and other normal tissues.
Fulvestrant ('Faslodex®') versus anastrozole ('Arimidex®') for the treatment of advanced breast cancer in postmenopausal women - safety update on the combined analysis of two multicenter trials.
Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women.
The third generation aromatase inhibitors provide consistent activity in patients with advanced breast cancer refractory to selective estrogen receptor modulators.
First-line therapy with letrozole (Femara®) for advanced breast cancer prolongs time to worsening of Karnofsky Performance Status compared with tamoxifen.
Preliminary analysis of the pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer.
Who is at increased risk of breast cancer if they use menopausal hormone replacement therapy?
Tibolone does not stimulate epithelial proliferation in the breast.
Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: initial results of Southwest Oncology Group S9626.
Changes in expression of estrogen receptor β in the transition from normal breast to breast cancer.
Nuclear BAG-1 expression predicts survival from breast cancer in patients treated with hormone therapy and potentiates oestrogen dependent transcription.
Three weeks of tamoxifen treatment alters the expression of ERα, ERβ and pS2.
Analysis of the estrogen receptor interaction with the corepressor HET/SAFB.
Role of estrogen receptor(ER)β in modulating ERα SERM complexes in MDA-MB-231 breast cancer cells.
ERα and ERαΔ5 expression in tamoxifen-treated breast tumours.
Changes in the expression of oestrogen receptors (ERα and ERβ) in the MCF7 cell line with endocrine treatments.
Functional interactions between extracellular matrix proteins and estrogen receptor α in modulating adhesion and motility in breast cancer cell lines.
Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk.
Detection of the androgen receptor in primary human breast cancer by multiparameter flow cytometry technique.
STAT 5a immunohistochemical determination in breast epithelium: absence of reactivity in abnormal cells.
ER+ high-grade breast carcinomas do not show myoepithelial differentiation.
Expression of cell adhesion molecules, CD44s and E-cadherin, in infiltrating micropapillary versus tubular carcinomas of the breast.
Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients.
Loss of CD63 expression as a prognostic marker in breast cancer.
Co-expression of ER and c-erb B2 in breast cancer.
Cyclooxygenase-2 is frequently overexpressed in human breast cancers.
Differential gene expression of selective TGF-β family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.
Lobular intraepithelial neoplasia: an examination of concurrent disease with grade and the implications for patient management.
Cytologic evaluation of duct washings does not reliably detect lactiferous duct pathology.
Biologic properties of breast lesions: results from a 12-center study of breast lesions using noninvasive electropotential measurements and results of the Post Market Surveillance.
Triple assessment in the preoperative diagnosis of invasive lobular breast carcinoma: a comparison of the individual modalities.
Pathologic nipple discharge has a high rate of associated malignancy: accurate clinical, galactographic, and surgical evaluation are essential.
Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial.
Preoperative trastuzumab (T) and paclitaxel (P) for HER2 overexpressing (HER2+) stage II/III breast cancer: clinical, pathological and serological findings.
A randomized phase II study of 4 or 6 cycles of Adriamycin/Taxol® (paclitaxel) as neoadjuvant treatment of breast cancer.
Dose-dense weekly (8 weeks) vs.sequential (24 weeks) neoadjuvant chemotherapy with adriamycin/cyclophosphamide and docetaxel in operable breast cancer (T2-3, N0-2, M0)-interim analysis of the Geparduo trial-.
Preliminary results of TOPIC (Trial of Primary Induction Chemotherapy): Navelbine-Epirubicin (NE) v Navelbine-Mitoxantrone (NM) v Adriamycin-Cyclophosphamide (AC) primary chemotherapy for >3 cm early breast cancer.
Disproportionate CNS relapse after aggressive neoadjuvant chemotherapy.
Neoadjuvant chemotherapy with Vinorelbine and Epirubicin in locally advanced breast cancer (LABC).
Neoadjuvant chemotherapy for locally advanced breast cancer: clinical and radiological response as predictors of local recurrence.
A phase II neoadjuvant trial of sequential doxorubicin and docetaxel for the treatment of stage III breast cancer measuring signal transducers and activators of transcription (STAT) activation as a predictor of response to therapy.
Cisplatin-epirubicin-vinorelbine: a new neoadjuvant chemotherapy for stage T2-3/N0-2 breast cancer patients.
High rate of axillary node clearence with neoadjuvant Herceptin, Taxotere, and Cisplatin in locally advanced advanced and inflammatory breast cancer.
Neoadjuvant chemotherapy in combined treatment of stage II breast cancer patients.
RNA yield from needle biopsies for cDNA microarray analysis of breast cancer prior to neoadjuvant chemotherapy.
Efficacy and tolerance of epirubicin-docetaxel (E-T) in patients with inflammatory breast cancer (IBC).
Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer.
Efficacy of Herceptin™ treatment on brain metastasis in women with HER2 overexpressing breast cancer.
Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: incidence and relation to clinical benefit.
Gemcitabine and trastuzamab for HER-2 positive metastatic breast cancer: preliminary results of a phase II study.
Pharmacokinetics (PK) of epirubicin (EPI) and docetaxel (DOCE) in combination with herceptin (H) in breast cancer patients.
Effect of cardiac dysfunction on treatment outcome in the Herceptin (trastuzumab) pivotal trial.
Survival benefit of Herceptin (trastuzumab) and chemotherapy in older (age>60) patients.
Increased breast cancer tumor localization and enhanced cytotoxicity of radioimmunotherapy and chemotherapy combinations.
Trastuzumab (herceptin™) monotherapy in patients with pretreated metastatic breast cancer.
Toxicity profiles: a comparative study of Herceptin (trastuzumab) and Taxol (paclitaxel) versus Herceptin, Taxol, and carboplatin in HER-2 positive patients with advanced breast cancer.
Targeted delivery of 1alpha(OH)D5 to Her-2+ breast cancer cells: inhibition of tumor growth.
Phase II study of the PPARγ-activating ligand troglitazone in treatment-refractory metastatic breast cancer.
Strategies to evaluate the clinical potential of botanical agents for breast cancer.
Novel therapeutic options for chronic neuropathic pain following axillary dissection for breast cancer.
Zometa® is equally effective as pamidronate: results of a phase III trial in breast cancer patients receiving chemotherapy.
Effect of clodronate on time to occurrence of skeletal complications in patients with breast cancer and bone metastases.
A randomized trial to examine effects of exercise on bone density and body composition in breast cancer patients receiving adjuvant chemotherapy.
The management of lobular neoplasia identified at percutaneous core breast biopsy.
Ambulatory breast surgery: post-operative symptoms and patients' satisfaction: assessment of a French cancer institute.
The effect of pregnancy on lymphedema.
Older women with breast cancer are less likely to receive adjuvant chemotherapy: evidence of possible age bias.
Femara®: preservation of quality of life in women undergoing second line hormonotherapy for breast cancer in a three month period.
Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer.
Preferences and attitudes of patients with metastatic breast cancer regarding receiving results information following participation in a clinical trial.
Usage patterns, perceived benefits, disadvantages, and accuracy of information in an online breast cancer support group.
Lymphatic mapping for male breast cancer.
Expression of serum and glucocorticoid-inducible kinase-1 transmits a survival signal in human mammary epithelial cells.
A role of p38 MAP kinase in drug-induced apoptosis in breast cancer cells?
Effect of antisense Bcl-2 and HER-2 for enhancement of drug-sensitivity associated with apoptosis in breast cancer cells.
Enhanced sensitivity of mammary carcinoma cell lines to the effects of the proteasome inhibitor PS-341 when Fas signal transduction is perturbed.
Protein kinase G induction and cyclic GMP phosphodiesterase inhibition by exisulind are used to induce apoptosis in breast tumor cells.
True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5.
Down-regulation of insulin-like growth factor 1 transcription in breast cancer compared to normal breast epithelium.
The relationship between serum androstenedione, dehydroepiandrosterone-sulphate, testosterone, and tumour androgen receptor expression in women with primary breast cancer.
Proliferative effect of medrogestone (Prothil®) on MCF-7 breast cancer cells.
A new response of estradiol in breast cancer: it can block estrone sulfatase activity in MCF-7 and T-47D breast cancer cells.
Development of an immuno-competent mouse breast tumor model for pre-clinical evaluation of Mage-b2 DNA vaccine.
Phase I clinical trial of HER2 peptide-pulsed autologous dendritic cells in patients with metastatic breast cancer (MBC).
Defective dendritic cell function in patients with breast cancer: reversal in vitro with cytokines.
Generation of cytokine activated antigen non-specific and dendritic cell primed Her2/neu peptide specific cytotoxic T cells from cord blood against human breast cancer.
C35 is a novel immunotherapy target expressed in human breast and bladder carcinoma.
Neutralization of vascular endothelial growth factor in activated T cell cultures improves generation of therapeutic effector cells for adoptive immunotherapy.
Axillary lymph node (LN) cellular immune response to Her-2/neu peptides in patients with carcinoma of the breast.
The molecular basis of inflammatory breast carcinoma.
Genetic profiles of risk of recurrence in node-negative breast cancers.
p190-B, an unconventional RhoGTPase activating protein, in cell invasion during ductal morphogenesis and mammary tumorignesis.
Polyamine involvement in invasion and metastasis by human breast cancer cells.
The Pyk2 kinase pathway is involved in hsp27-induced breast tumor invasiveness.
TGF β signaling in osteolytic cancer cell lines: stimulation of IL-6, IL-11, PTHrP, and VEGF through MAP kinase pathways.
Breast cancer cells directly induce the differentiation of RAW264.7 cells into functional osteoclasts.
Characterization of MTA1 expression in breast cancer.
Inhibition of human osteoblast proliferation and mineralization by breast cancer cell-derived paracrine factors.
Heat shock protein 27 is involved in the turnover of c-Yes mRNA in human breast cancer cells leading to increased invasiveness.
Expression of the (αV)β3 integrin enhances osteopontin-induced cell adhesion, migration and invasion, but not anchorage-independent growth, of 21NT mammary epithelial cells.
Galectin 9 as an excellent functional predictive factor for metastasis of breast cancer.
The HGF/SF antagonist NK4 reduces tumour invasion and growth in breast cancer models.
Differential expression of maspin in human breast cancer and its implications on prognosis.
Gene amplification of HER-2/neu is inversely correlated with loss of expression of the tetraspanin metastasis suppressor gene, KAI1/CD82, in breast cancer samples and cell lines.
Implication of the activation of matrix metalloproteinase-2 on the metastasis in breast cancer.
The role of the type I insulin-like growth factor receptor (IGF-IR) in regulating tissue type plasminogen activator (tPA) in human breast cancer cells.